Flora Mulkey

2.4k citations
34 papers · 1.5k · h-index 17

Impact in

Papers in

  • Oncology 13
    • Cancer Immunotherapy and Biomarkers 6
    • Colorectal Cancer Treatments and Studies 4
  • Hematology 11
    • Acute Myeloid Leukemia Research 5
    • Multiple Myeloma Research and Treatments 5
Co-authors
Rajeshwari Sridhara (9 shared papers)William Maixner (4 shared papers)Roger B. Fillingim (4 shared papers)Richard Ohrbach (4 shared papers)Joel D. Greenspan (4 shared papers)Gary D. Slade (3 shared papers)Sirisha L. Mushti (4 shared papers)Charles Knott (3 shared papers)
Journals
Journal of Clinical Oncology (6 papers)Blood (4 papers)Journal of Pain (4 papers)Clinical Cancer Research (2 papers)Statistics in Biopharmaceutical Research (2 papers)
Partner nations
United StatesJapanUnited Kingdom

In The Last Decade

Flora Mulkey

31 papers receiving 1.5k citations

Peers

Flora Mulkey
Comparison fields: 5 of 93
  • Complementary and Manual Therapy 418
  • Hematology 306
  • Oncology 365
  • Physiology 212
  • Neurology 104
Replace Tetsu Yamamoto with:
Tetsu Yamamoto Japan
Gary Milligan United Kingdom
Alessandra Bortoluzzi Italy
João Carlos Tavares Brenol Brazil
J. Christiaan van Denderen Netherlands
Sławomir Jeka Poland
Renee Perdok United States
Wataru Yamamoto Japan
Kai-Hua Chen China
Alexander So Switzerland
Flora Mulkey relative to Tetsu Yamamoto Japan Tetsu Yamamoto's profile →
Citations per field
00.5×5×10×15×20×23.5×
Tetsu Yamamoto · 1×
Citations per year

Countries citing papers authored by Flora Mulkey

Since Specialization
Citations

This map shows the geographic impact of Flora Mulkey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Flora Mulkey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Flora Mulkey more than expected).

Fields of papers citing papers by Flora Mulkey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Flora Mulkey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Flora Mulkey. The network helps show where Flora Mulkey may publish in the future.

Co-authors

The 25 scholars most cited alongside Flora Mulkey, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Flora Mulkey Line = papers co-authored together Flora Mulkey links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 34 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Clinical Findings and Pain Symptoms as Potential Risk Factors for Chronic TMD: Descriptive Data and Empirically Identified Domains from the OPPERA Case-Control Study
Journal of Pain ·Richard Ohrbach, Roger B. Fillingim, Flora Mulkey, Yoly González, Sharon M. Gordon, Henry A. Gremillion, Pei-Feng Lim, Margarete Ribeiro-Dasilva, Joel D. Greenspan, Charles Knott, William Maixner, Gary D. Slade
2011281
2
Pain Sensitivity Risk Factors for Chronic TMD: Descriptive Data and Empirically Identified Domains from the OPPERA Case Control Study
Journal of Pain ·Joel D. Greenspan, Gary D. Slade, Eric Bair, Ronald Dubner, Roger B. Fillingim, Richard Ohrbach, Charlie Knott, Flora Mulkey, Rebecca Rothwell, William Maixner
2011167
3
Study Methods, Recruitment, Sociodemographic Findings, and Demographic Representativeness in the OPPERA Study
Journal of Pain ·Gary D. Slade, Eric Bair, Kunthel By, Flora Mulkey, Cristina Baraian, Rebecca Rothwell, Maria Reynolds, Vanessa Miller, Yoly González, Sharon M. Gordon, Margarete Ribeiro-Dasilva, Pei Feng Lim, Joel D. Greenspan, Ron Dubner, Roger B. Fillingim, Luda Diatchenko, William Maixner, Dawn Dampier, Charles Knott, Richard Ohrbach
2011127
4
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis
The Lancet Oncology ·Julia A. Beaver, Maitreyee Hazarika, Flora Mulkey, Sirisha L. Mushti, Huanyu Chen, Kun He, Rajeshwari Sridhara, Kirsten B. Goldberg, Meredith K. Chuk, Dow-Chung Chi, Jennie Chang, Amy Barone, Sanjeeve Balasubramaniam, Gideon M. Blumenthal, Patricia Keegan, Richard Pazdur, Marc R. Theoret
2018114
5
Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials
Clinical Cancer Research ·Sirisha L. Mushti, Flora Mulkey, Rajeshwari Sridhara
2018112
6
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502
Journal of Clinical Oncology ·Steven M. Devine, Kouros Owzar, William Blum, Flora Mulkey, Richard M. Stone, Jack W. Hsu, Richard E. Champlin, Yi‐Bin Chen, Ravi Vij, James L. Slack, Robert J. Soiffer, Richard A. Larson, Thomas C. Shea, Vera Hárs, Alexander B. Sibley, Sergio Giralt, Shelly Carter, Mary M. Horowitz, Charles Linker, Edwin P. Alyea
2015106
7
Potential Autonomic Risk Factors for Chronic TMD: Descriptive Data and Empirically Identified Domains from the OPPERA Case-Control Study
Journal of Pain ·William Maixner, Joel D. Greenspan, Ronald Dubner, Eric Bair, Flora Mulkey, Vanessa Miller, Charles Knott, Gary D. Slade, Richard Ohrbach, Luda Diatchenko, Roger B. Fillingim
201194
8
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance)
Haematologica ·Meir Wetzler, D. Watson, Wendy Stock, Greg Koval, Flora Mulkey, Eva Hoke, John M. McCarty, William Blum, Bayard L. Powell, Guido Marcucci, C. D. Bloomfield, Claudia Linker, Richard A. Larson
201374
9
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
Journal for ImmunoTherapy of Cancer ·Flora Mulkey, Marc R. Theoret, Patricia Keegan, Richard Pazdur, Rajeshwari Sridhara
202062
10
FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non–small Cell Lung Cancer, A Collaborative Project Orbis Review
Clinical Cancer Research ·Paz J. Vellanki, Flora Mulkey, Adnan A. Jaigirdar, Lisa Rodríguez, Yibo Wang, Yuan Xu, Hong Zhao, Jiang Liu, Grant A. Howe, Jian Wang, Qiuyi Choo, Sarah J. Golding, Victoria Mansell, Kwadwo Ameyaw Korsah, Dianne Spillman, R. Angelo de Claro, Richard Pazdur, Julia A. Beaver, Harpreet Singh
202144
11
Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from fourCALGB(alliance) clinical trials
American Journal of Hematology ·Jorge J. Castillo, Flora Mulkey, Susan Geyer, Jonathan E. Kolitz, William Blum, Bayard L. Powell, Stephen L. George, Richard A. Larson, Richard M. Stone
201540
12
Clinical impact ofABL1kinase domain mutations andIKZF1deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665
Leukemia & lymphoma ·Rebecca DeBoer, Gregory Koval, Flora Mulkey, Meir Wetzler, Steven M. Devine, Guido Marcucci, Richard M. Stone, Richard A. Larson, Clara D. Bloomfield, Susan Geyer, Charles G. Mullighan, Wendy Stock
201638
13
Genomewide Meta‐Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent‐Induced Sensory Peripheral Neuropathy
Clinical Pharmacology & Therapeutics ·Katherina C. Chua, Chenling Xiong, Carol Ho, Taisei Mushiroda, J Chen, Flora Mulkey, Dongbing Lai, Bryan P. Schneider, Sara R. Rashkin, John S. Witte, Paula N. Friedman, Mark J. Ratain, Howard L. McLeod, Hope S. Rugo, Lawrence N. Shulman, Michiaki Kubo, Kouros Owzar, Deanna L. Kroetz
202028
14
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration‐resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)
Cancer ·Jai N. Patel, Chen Jiang, Daniel L. Hertz, Flora Mulkey, Kouros Owzar, Susan Halabi, Mark J. Ratain, Paula N. Friedman, Eric J. Small, Michael A. Carducci, John F. Mahoney, Michael J. Kelley, Michael J. Morris, William Kevin Kelly, Howard L. McLeod
201427
15
Alliance A061202. a Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Versus Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor Based Therapy: Phase I Results
Blood ·Peter M. Voorhees, Flora Mulkey, Hani Hassoun, Claudia E. Paba‐Prada, Yvonne A. Efebera, Eva Hoke, Guadalupe Aquino, Destin Carlisle, Vera J. Suman, Paul G. Richardson
201519
16
Incidence of Differentiation Syndrome with Ivosidenib (IVO) and Enasidenib (ENA) for Treatment of Patients with Relapsed or Refractory (R/R) Isocitrate Dehydrogenase (IDH)1- or IDH2-Mutated Acute Myeloid Leukemia (AML): A Systematic Analysis By the U.S. Food and Drug Administration (FDA)
Blood ·Kelly J. Norsworthy, Flora Mulkey, Ashley F. Ward, Donna Przepiorka, Albert Deisseroth, Ann T. Farrell, Richard Pazdur
201818
17
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)
American Journal of Hematology ·Peter M. Voorhees, Vera J. Suman, Sascha A. Tuchman, Jacob P. Laubach, Hani Hassoun, Yvonne A. Efebera, Flora Mulkey, Misty Bova‐Solem, Katelyn Santo, Destin Carlisle, Philip L. McCarthy, Paul G. Richardson
202117
18
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)
Investigational New Drugs ·Pankaj Gupta, Flora Mulkey, Robert P. Hasserjian, Ben L. Sanford, Ravi Vij, David D. Hurd, Olatoyosi Odenike, Clara D. Bloomfield, Kouros Owzar, Richard M. Stone, Richard A. Larson
201316
19
FDA analysis of depth of response (DpR) and survival across 10 randomized controlled trials in patients with previously untreated unresectable or metastatic melanoma (UMM) by therapy type.
Journal of Clinical Oncology ·Christy Osgood, Flora Mulkey, Pallavi S. Mishra‐Kalyani, Steven J. Lemery, Ashley V. Ward, Patricia Keegan, Rajeshwari Sridhara, Marc R. Theoret, Richard Pazdur
201915
20
FDA analysis of pembrolizumab trials in multiple myeloma: Immune related adverse events (irAEs) and response.
Journal of Clinical Oncology ·Aviva C. Krauss, Flora Mulkey, Yuan-Li Shen, Amy S. Rosenberg, Barry W. Miller, Theresa Carioti, K.W. Scott, Nicole Gormley, Marc R. Theoret, Rajeshwari Sridhara, Ann T. Farrell, Richard Pazdur
201815

About Flora Mulkey

Flora Mulkey is a scholar working on Oncology, Hematology, Molecular Biology, Cancer Research and Statistics and Probability, having authored 34 papers that have together received 1.5k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (6 papers), Statistical Methods in Clinical Trials (6 papers), Cancer Genomics and Diagnostics (5 papers), Acute Myeloid Leukemia Research (5 papers), Multiple Myeloma Research and Treatments (5 papers), Colorectal Cancer Treatments and Studies (4 papers), Acute Lymphoblastic Leukemia research (4 papers) and Temporomandibular Joint Disorders (4 papers). The work is most often cited by research in Complementary and Manual Therapy (418 citations), Hematology (306 citations), Oncology (365 citations), Physiology (212 citations) and Neurology (104 citations). Flora Mulkey has collaborated with scholars based in United States, Japan and United Kingdom. Frequent co-authors include Rajeshwari Sridhara, William Maixner, Roger B. Fillingim, Richard Ohrbach, Joel D. Greenspan, Gary D. Slade, Sirisha L. Mushti, Charles Knott, Eric Bair and Sharon M. Gordon. Their work appears in journals such as Journal of Clinical Oncology, Blood, Journal of Pain, Clinical Cancer Research and Statistics in Biopharmaceutical Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tetsu YamamotoBreakdown of academic impact, for papers by Gary MilliganBreakdown of academic impact, for papers by Alessandra BortoluzziBreakdown of academic impact, for papers by João Carlos Tavares BrenolBreakdown of academic impact, for papers by J. Christiaan van DenderenBreakdown of academic impact, for papers by Sławomir JekaBreakdown of academic impact, for papers by Renee PerdokBreakdown of academic impact, for papers by Wataru YamamotoBreakdown of academic impact, for papers by Kai-Hua ChenBreakdown of academic impact, for papers by Alexander So